<DOC>
	<DOCNO>NCT00945269</DOCNO>
	<brief_summary>RATIONALE : White blood cell treat laboratory may able kill tumor cell patient melanoma . Aldesleukin denileukin diftitox may stimulate white blood cell kill melanoma cell . Giving therapeutic autologous lymphocyte therapy together aldesleukin denileukin diftitox may kill tumor cell . PURPOSE : This phase I/II trial study side effect give therapeutic autologous lymphocytes together aldesleukin denileukin diftitox see well work treat patient stage III-IV melanoma</brief_summary>
	<brief_title>Therapeutic Autologous Lymphocytes , Aldesleukin , Denileukin Diftitox Treating Patients With Stage III-IV Melanoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Assess safety cellular adoptive immunotherapy melanoma patient use autologous CD8+ antigen-specific T-cell clone follow CD25 lymphodepletion . II . Determine influence CD25 lymphodepletion duration vivo persistence adoptively transfer CD8+ antigen-specific cytotoxic T-cell ( CTL ) clone . SECONDARY OBJECTIVES : I. Assess anti-tumor efficacy cellular adoptive immunotherapy melanoma patient use autologous CD8+ antigen-specific T cell clone follow CD25 lymphodepletion . II . Evaluate induction T cell non-targeted tumor-associated antigen ( antigen-spreading ) follow adoptive transfer CD8+ antigen-specific CTL CD25 lymphodepletion . OUTLINE : This phase I study follow phase II study . Patients receive autologous T-cell intravenously ( IV ) 30-60 minute day 0 28 low-dose aldesleukin subcutaneously ( SC ) twice daily day 0 13 28 41 . Beginning 4-6 day second T- cell infusion , patient receive denileukin diftitox IV 30 minute day 1-3 . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow 4 week , 8 week , every 3 month thereafter .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Histopathological documentation melanoma Expression human leukocyte antigen ( HLA ) A2 B44 determine HLA type lab Patients whose tumor express target antigen restrict allele CD8 T cell clone generate Karnofsky Performance status least 80 % expect survival great 6 month Bidimensionally measurable disease palpation clinical exam , radiographic imaging ( Xray , compute tomography [ CT ] scan ) Normal cardiac stress test ( treadmill , echocardiogram , myocardial perfusion scan ) within 182 day prior enrollment required patient history cardiac disease Pulse &gt; 45 &lt; 120 Weight &gt; = 45 kg Temperature = &lt; 38C ( &lt; 100.4 F ) White blood cell ( WBC ) &gt; = 3,000 Hematocrit ( HCT ) &gt; = 30 % Platelets &gt; = 100,000 Patients must willing able discontinue use antihypertensive medication 24 hour prior IL2 therapy Pregnant woman , nurse mother , woman reproductive ability unwilling use effective contraception abstinence Serum creatinine &gt; 1.6mg/dL Creatinine clearance &lt; 75 ml/min Aspartate aminotransferase ( AST ) &gt; 2.5 x upper limit normal Alanine aminotransferase ( ALT ) &gt; 2.5 x upper limit normal Bilirubin &gt; 1.6 international normalize ratio ( INR ) &gt; 1.5 due hepatic dysfunction Albumin &lt; 3.0g/dL Clinically significant pulmonary dysfunction , determine medical history physical exam ; patient identify undergo pulmonary function test Forced expiratory volume one second ( FEV1 ) &lt; 80 % predict diffusing capacity lung carbon monoxide ( DLco ) ( corr hemoglobin [ Hgb ] ) &lt; 75 % exclude Significant cardiovascular abnormality define one following : congestive heart failure , symptom coronary artery disease Symptomatic central nervous system ( CNS ) metastases great 1 cm time therapy ; patient 12 asymptomatic , less 1cm brain/CNS metastasis without significant edema may consider treatment Patients active infection oral temperature &gt; 38.2 C within 48 hour study entry systemic infection require chronic maintenance suppressive therapy Chemotherapeutic agent ( standard experimental ) , radiation therapy , immunosuppressive therapy less 3 week prior T cell therapy ) Concurrent treatment steroid Patients must receive experimental drug within 3 week initiation protocol must recover side effect therapy The following agent allow study : systemic corticosteroid ( except outline management toxicity nontransduced CTL ) , immunotherapy ( example , interleukin , interferon , melanoma vaccine , intravenous immunoglobulin , expand polyclonal TIL LAK therapy ) , pentoxifylline , investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>